Oncolytic Probiotics Mediated Kidney Cancer Treatment

Kidney cancer also called renal cell carcinoma (RCC), is a highly vascular tumor in which kidney cells become malignant (cancerous) and grow out of control, forming a tumor. Targeted therapy drugs target specific functions or genes that play a significant role in the development of cancer. They intervene the functions that are necessary for cancer to survive and grow.

Biological pathways and therapeutic targeted agents for renal cell carcinoma.

Fig.1 Biological pathways and therapeutic targeted agents for renal cell carcinoma.

Targeted cancer drugs work by targeting specific genes and proteins in cancer cells that help them to grow and survive. Targeted therapy drugs which are generally available for kidney cancer are listed below.

Target Types Agent Manufacturer Start Marketing Date
IL2RA, IL2RB, IL2RG Peptide immunopotentiator Proleukin CHIRON 1992
VEGFR-1, VEGFR-2, VEGFR-3, PDGFR, c-KIT Small molecule Inlyta Pfizer 2012
VEGFR mAb Avastin Roche 2004
c-MET, VEGFR-2, FLT-3, c-KIT, RET Small molecule Cabometyx Exelixis 2016
mTOR Small molecule Certican Afinitor Zortress Novartis 2009
RTK/FLT1, KDR, FLT4, FGFR1, FGFR2, FGFR3, PDGFRB Small molecule Lenvima ESAL 2015
PD-L1 mAb Opdivo BMS 2014
VEGFR-1, VEGFR-2, VEGFR-3, PDGFR, FGFR, c-KIT Small molecule Votrient Novartis 2009
KIT, VEGFR, PDGFR, RAF Small molecule Nexavar Bayer 2005
VEGFR, PDGFR, KIT Small molecule Sutent Pfizer 2006
mTOR Small molecule Torisel PF Prism CV 2007

As a novel delivery system, bacterial were conceived as potential cancer therapeutics. We are committed to providing oncolytic bacteria genome editing service to best meet your research goals, with reduced turnaround time and lower prices. If you have any question, please feel free to contact us at . We will propose the best strategy for you.

Workflow:

Workflow

The advantages in Creative Biogene:

• Fast turnaround time, lower price
• higher efficiency and success rate
• Rich experience
• Markerless genome editing
• Easy selection: no selectable marker is required

Reference
1. Cho, I. C. , & Chung, J. . (2012). Current status of targeted therapy for advanced renal cell carcinoma. Korean journal of urology, 53(4), 217-228.

For research use only.

Quick Inquiry

  • Verification code

Creative Biogene is fully engaged in developing unique technologies that provide global scientists with high quality products and satisfactory services to facilitate the investigation of microbial researches.

Subscribe

Enter your email address to subscribe.

Microbial Fermentation

• Microbial Fermentation Service

Copyright © Creative Biogene. All Rights Reserved.